Drugs / Losartan
Losartan
also known as
losartan potassium · Cozaar · MK0954 · COZZAR · HGP1405 · Allisartan · Angizaar · Aradois · +30 more
Other / unclassified targets AGTR1, TGFB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | COZAAR | — | 1995-12-29 – 2004-03-11 | fda.gov ↗ |
| Approved | US (FDA) | COZAAR | — | 1995-04-14 | fda.gov ↗ |
Trials 252 · started per year
today
US approved 1995
1
2
1
2
1
2
1
3
5
8
8
13
6
14
14
7
7
14
6
10
10
6
9
7
16
6
21
8
10
7
13
6
6
1
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 015 trials | ||||||
| Phase 0 | NCT07017023 | Jul 2025 → Dec 2026 expected | — | University of Oxford | Recruiting | No outcome recorded |
| Phase 0 | NCT06693960 | Sep 2024 → Dec 2026 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06624904 | Aug 2024 → Oct 2025 | CGF1 | University of Oxford | Completed | No outcome recorded |
| Phase 0 | NCT06628154 | Aug 2024 → Jul 2025 overdue | — | University of Oxford | Recruiting | No outcome recorded |
| Phase 0 | NCT06636812 | Mar 2024 → Dec 2025 overdue | — | University of Oxford | Recruiting | No outcome recorded |
| Phase 0 | NCT05607017 | Sep 2023 → Oct 2025 | breast cancer, radiation-induced disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT05576155 | Oct 2022 → Feb 2023 | — | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 0 | NCT03435939 | Feb 2022 → Sep 2025 | cystic fibrosis | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT05365893 | Oct 2021 → Dec 2025 overdue | pancreatic ductal adenocarcinoma | Fox Chase Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05132712 | Oct 2021 → Sep 2022 | — | Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi | Unknown | No outcome recorded |
| Phase 0 | NCT04632589 | Nov 2020 → Jun 2024 | preeclampsia | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 0 | NCT03147092 | Feb 2018 → Jun 2020 | hypertensive disorder | Centro Neurológico de Pesquisa e Reabiitação, Brazil | Unknown | No outcome recorded |
| Phase 0 | NCT02744456 | Aug 2014 → Aug 2017 | hypertensive disorder | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT01989078 | Dec 2012 → Dec 2016 | sickle cell disease | Emory University | Completed | No outcome recorded |
| Phase 0 | NCT01276613 | Jan 2011 → Apr 2019 | malignant pancreatic neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 135 trials · 2 met primary | ||||||
| Phase 1 | NCT07784621 | Oct 2026 → Feb 2027 expected | hypertensive disorder | Huons Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300670 | Mar → May 2026 | — | Aleksi Tornio | Completed | No outcome recorded |
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06831864 | Feb → May 2025 | symptomatic heart failure | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT06211335 | Dec 2023 → Dec 2026 expected | head and neck squamous cell carcinoma | University of California, Davis | Recruiting | No outcome recorded |
| Phase 1 | NCT07823140 | Aug 2022 → Apr 2023 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 1 | NCT04201197 | Nov 2020 → Mar 2022 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04504045 | Sep 2020 → May 2022 | type 2 diabetes mellitus | University of Southern Denmark | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04335123 | Apr → Jun 2020 | COVID-19 | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03900793 | Aug 2019 → Aug 2027 expected | osteosarcoma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT04106856 | Aug 2019 → Dec 2024 | pancreatic ductal adenocarcinoma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT04322266 | Dec 2018 → Feb 2019 | — | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 1 | NCT04081844 | May → Jun 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03505853 | Apr → Nov 2018 | acute intermittent porphyria | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03864042 | Jan 2018 → Jul 2022 | cancer, metastatic melanoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04252872 | Aug → Nov 2015 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02387554 | Aug → Oct 2014 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02212769 | Aug 2014 → Jan 2015 | — | Dong Wha Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01934569 | Sep → Nov 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02056743 | Sep → Oct 2013 | — | Chonbuk National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01692717 | Feb → May 2013 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 1 | NCT01648231 | Aug → Sep 2012 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01806324 | Apr → Nov 2012 | hyperlipidemia, hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01443039 | Sep 2011 → Feb 2014 | obesity disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT01386593 | May 2011 → Jan 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01292694 | Mar 2011 → Mar 2017 | hypertensive disorder, pure autonomic failure | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01324752 | Mar → Jun 2011 | — | Vifor Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01198249 | Sep 2010 → Feb 2011 | essential hypertension | Yonsei University | Completed | No outcome recorded |
| Phase 1 | NCT01087749 | Mar 2010 → Dec 2012 | chronic kidney disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT03912285 | Jan 2008 → Mar 2009 | — | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01033318 | Sep 2007 → Jun 2008 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01149486 | Jan → Feb 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01124175 | Oct → Nov 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT05893108 | Mar → Sep 2024 | keloid | Yuni Eka Anggraini | Unknown | No outcome recorded |
| Phase 1/2 | NCT06143566 | Mar 2024 → Sep 2027 expected | hypertensive disorder, type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06108063 | Mar 2024 → Jun 2027 expected | osteoarthritis, knee | Steadman Philippon Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04815902 | May 2021 → Feb 2025 | osteoarthritis, knee | Steadman Philippon Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT04212650 | Aug → Dec 2020 | articular cartilage disorder, osteoarthritis, hip | Steadman Philippon Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT02769130 | May 2016 → May 2021 | primary pulmonary vein stenosis | The Hospital for Sick Children | Suspended | No outcome recorded |
| Phase 1/2 | NCT01384591 | Jul 2011 → May 2015 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1/2 | NCT01086722 | Feb 2010 → Feb 2013 | morbid obesity | Hospital del Mar Medical Research Institute (IMIM) | Completed | No outcome recorded |
| Phase 1/2 | NCT00467831 | Apr 2007 → Nov 2012 | Hermansky-Pudlak syndrome, oculocutaneous albinism, platelet storage pool deficiency, pulmonary fibrosis | National Human Genome Research Institute (NHGRI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 245 trials · 5 met primary · 3 missed | ||||||
| Phase 2 | NCT07265739 | Feb → Dec 2027 expected | refractory malignant neoplasm | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06933706 | Oct 2025 → Sep 2029 expected | — | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06364176 | Jun 2024 → May 2027 expected | cystic fibrosis | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06135493 | Dec 2023 → Mar 2025 | chemotherapy-induced neuropathy | Future University in Egypt | Completed | Met primary |
| Phase 2 | NCT05637216 | Aug 2023 → Aug 2027 expected | radiation-induced disorder | Shaw Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05871333 | Jul 2023 → Jun 2024 | chemotherapy-induced oral mucositis, colorectal cancer, gastrointestinal mucositis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT05861336 | Jun 2023 → Dec 2024 | malignant pancreatic neoplasm | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05331144 | Oct 2022 → Jun 2027 expected | hereditary dementia, hypertensive disorder, subjective cognitive decline | Rong Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT05370599 | Apr 2022 → Jan 2026 | hypertensive disorder | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05077800 | Mar 2022 → Dec 2026 expected | pancreatic adenocarcinoma | Colin D. Weekes, M.D., PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05232370 | Jan 2022 | — | Unidad de Investigacion Medica en Enfermedades Renales | Completed | No outcome recorded |
| Phase 2 | NCT05097248 | Oct 2021 → Oct 2024 | breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05012631 | Sep 2021 → Oct 2025 | sickle cell disease | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT04539808 | May 2021 → Dec 2024 overdue | pancreatic adenocarcinoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04643691 | Sep 2020 → Dec 2021 | COVID-19, acute respiratory distress syndrome | Assistance Publique Hopitaux De Marseille | Terminated | No outcome recorded |
| Phase 2 | NCT04447235 | Jul 2020 → Jun 2022 | COVID-19, cancer | Cancer Institute of the State of São Paulo | Terminated | No outcome recorded |
| Phase 2 | NCT04312009 | Apr 2020 → Feb 2021 | COVID-19, acute respiratory distress syndrome | University of Minnesota | Completed | Missed primary |
| Phase 2 | NCT04311177 | Apr 2020 → Feb 2021 | COVID-19, acute respiratory distress syndrome | University of Minnesota | Completed | Missed primary |
| Phase 2 | NCT04428268 | Mar → Jun 2020 | pneumonia | Hospital Universitario Dr. Jose E. Gonzalez | Withdrawn | No outcome recorded |
| Phase 2 | NCT03951142 | Oct 2019 → Oct 2024 | glioblastoma, metastatic malignant neoplasm in the brain | Kyrre Eeg Emblem | Unknown | No outcome recorded |
| Phase 2 | NCT03563248 | Aug 2018 → Feb 2022 overdue | malignant pancreatic neoplasm | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03206788 | Nov 2017 → Oct 2019 | cystic fibrosis | University of Miami | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03029091 | May 2017 → Jul 2019 | eosinophilic esophagitis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT02676466 | Apr 2016 → Jun 2018 | — | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02278471 | Dec 2015 → Jun 2018 | hyperlipidemia, hypertensive disorder | Vanderbilt University | Completed | Met primary |
| Phase 2 | NCT02560805 | Oct 2015 → Mar 2027 expected | post-traumatic stress disorder | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT02663141 | Jun 2015 → Jun 2016 | diabetic macular edema | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02373241 | Apr 2015 → Feb 2021 | hypertensive disorder, proteinuria, sickle cell disease | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2 | NCT01852942 | Sep 2014 → Jul 2019 | HIV infectious disease | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01808196 | Oct 2013 → Jan 2015 | connective tissue disorder, eosinophilic esophagitis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01821729 | Aug 2013 → Feb 2018 | malignant pancreatic neoplasm | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01913470 | Jul 2013 → Dec 2015 | fatty liver disease | Miriam Vos, MD | Completed | No outcome recorded |
| Phase 2 | NCT01479439 | Feb 2012 → Nov 2015 | sickle cell disease | Children's Hospital Medical Center, Cincinnati | Completed | Met primary |
| Phase 2 | NCT01398423 | Jun 2011 → Jul 2012 | hypertensive disorder, type 2 diabetes mellitus | InVasc Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01320397 | May 2011 → Jul 2012 | essential hypertension | RostaQuo S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT01234922 | Feb 2011 → Dec 2013 | cancer of unknown primary site, hypertensive disorder | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01224860 | Jan 2009 → Jun 2013 | — | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT00593710 | Jan 2008 → Oct 2010 | Marfan syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00942344 | May → Dec 2007 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | Mixed |
| Phase 2 | NCT00699036 | Apr 2007 → Jul 2009 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Brooke Army Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00388388 | Mar 2007 → Dec 2009 | hypertensive disorder, prediabetes syndrome | Sir Mortimer B. Davis - Jewish General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01150461 | Feb 2007 → Jul 2010 | hypertrophic cardiomyopathy | Massachusetts General Hospital | Completed | Met primary |
| Phase 2 | NCT00651235 | Feb 2007 → Feb 2011 | Marfan syndrome | National Taiwan University Hospital | Unknown | Met primary |
| Phase 2 | NCT00381134 | Jul 2003 → Dec 2006 | diabetes mellitus, diabetic kidney disease, hypertensive disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00143949 | Mar 1997 → Mar 2007 | type 1 diabetes mellitus | Michael Mauer, MD | Completed | Missed primary |
| Phase 2/36 trials · 1 missed | ||||||
| Phase 2/3 | NCT04349410 | Apr → Sep 2020 | COVID-19 | The Camelot Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT04328012 | Apr 2020 → Jul 2021 | Orthocoronavirinae infectious disease | Bassett Healthcare | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02913664 | Feb 2017 → Nov 2021 | hypertensive disorder, subjective cognitive decline | University of Texas Southwestern Medical Center | Completed | Missed primary |
| Phase 2/3 | NCT02410005 | Oct 2014 → Sep 2015 | diabetic kidney disease | Weill Cornell Medical College in Qatar | Terminated | No outcome recorded |
| Phase 2/3 | NCT00981747 | Sep 2009 → Dec 2016 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Alicia Gerke | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT00284128 | Dec 2005 → Mar 2008 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 345 trials · 6 met primary · 5 missed | ||||||
| Phase 3 | NCT07569640 | Aug 2026 → Apr 2029 expected | symptomatic heart failure | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT06150560 | Apr 2024 → Jun 2028 expected | aorta coarctation, hypertensive disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT04927299 | Jun 2022 → Aug 2023 | essential hypertension | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT04591210 | Jan 2021 → Dec 2024 | COVID-19, cardiovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04606563 | Oct 2020 → Apr 2022 | COVID-19 | University of British Columbia | Terminated | Missed primary |
| Phase 3 | NCT04343001 | Oct 2020 → Apr 2021 | COVID-19 | London School of Hygiene and Tropical Medicine | Withdrawn | No outcome recorded |
| Phase 3 | NCT01620788 | Nov 2019 → Jul 2023 | hypertensive disorder | EMS | Suspended | No outcome recorded |
| Phase 3 | NCT03357653 | Jan 2018 → Dec 2021 | IgA glomerulonephritis | Ewha Womans University | Unknown | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02232776 | Oct 2014 → Dec 2016 | IgA glomerulonephritis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02232763 | Sep 2014 → Jul 2016 | proteinuria | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02899455 | Jul 2014 → Jun 2016 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT01307046 | Mar 2011 → Feb 2012 | essential hypertension | Organon and Co | Completed | Met primary |
| Phase 3 | NCT01307033 | Mar 2011 → Dec 2012 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00971165 | Jul 2010 → Sep 2014 | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00782327 | Nov 2009 → Nov 2014 | Marfan syndrome | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 3 | NCT01127217 | May 2009 → Mar 2010 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT00756938 | Mar 2009 → Aug 2012 | hypertensive disorder | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT01145612 | Oct 2008 → Feb 2013 | Marfan syndrome | Forteza, Albert, M.D. | Unknown | No outcome recorded |
| Phase 3 | NCT00683124 | Jul 2008 → Jul 2013 | Marfan syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00940667 | May → Dec 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT00659451 | Apr 2008 | diabetes mellitus, essential hypertension | University of Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00568178 | Jun 2007 → Sep 2008 | proteinuria | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00546754 | May 2007 → Apr 2009 | hypertensive disorder | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT00354991 | Jun 2006 → Apr 2007 | essential hypertension | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00449111 | Mar → Sep 2006 | hypertensive disorder | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00289887 | Feb 2006 → Feb 2007 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00219141 | Oct 2005 → Nov 2007 | essential hypertension, heart disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00546052 | Sep 2005 → Jan 2008 | hypertensive disorder, metabolic disease | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT00400218 | Sep 2005 → Jul 2006 | essential hypertension | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00398541 | Mar 2005 → Apr 2007 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00307060 | Dec 2004 → Jun 2005 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00133185 | Mar 2004 → Mar 2005 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00151827 | Aug 2003 → Jul 2005 | essential hypertension, impaired renal function disease | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00362960 | May 2003 → Sep 2004 | diabetic kidney disease, proteinuria, type 2 diabetes mellitus | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00092209 | Apr → Nov 2002 | essential hypertension | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090259 | Dec 2001 → Mar 2009 | heart failure | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00541684 | Jul 2001 → Jan 2003 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00308347 | May 1996 → Feb 2001 | diabetic kidney disease, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00340678 | Aug 1995 → May 2012 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 3 | NCT00338260 | Jun 1995 → Sep 2001 | hypertensive heart disease | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00888355 | May 1992 → Jan 1993 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00887250 | Dec 1991 → Aug 1992 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00886600 | May 1991 → May 1992 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00882440 | Dec 1990 → Aug 1991 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 460 trials · 3 met primary · 5 missed | ||||||
| Phase 4 | NCT07135687 | Aug 2026 → Oct 2028 expected | — | Rush University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07704658 | Jun 2026 → Jul 2027 expected | non-small cell lung carcinoma, thyroid cancer | Rigel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT07160361 | Oct 2025 → Dec 2028 expected | hepatocellular carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07099859 | Jul 2025 → Jul 2029 expected | aortic valve insufficiency, congestive heart failure | Vitor Emer Egypto Rosa | Recruiting | No outcome recorded |
| Phase 4 | NCT06333522 | Jul 2024 → Jan 2026 | arthropathy | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT05157464 | Sep 2023 → Dec 2024 | ankylosis | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05402397 | Jul 2022 → Dec 2023 | acute urate nephropathy | Hospital General de Niños Pedro de Elizalde | Completed | No outcome recorded |
| Phase 4 | NCT04715568 | Mar 2021 → Dec 2026 expected | hypertensive disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT04238702 | Nov 2020 → Sep 2021 | diabetic kidney disease, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT04340557 | Mar → Jun 2020 | COVID-19 | Sharp HealthCare | Completed | No outcome recorded |
| Phase 4 | NCT03978884 | Jun 2019 → May 2020 | diabetes mellitus, hypertensive disorder | The University of The West Indies | Withdrawn | No outcome recorded |
| Phase 4 | NCT03692013 | Dec 2018 → Jun 2023 | hypertensive nephropathy | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT03666351 | Oct 2018 → Jul 2022 | aortic valve insufficiency, aortic valve stenosis, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 4 | NCT03946514 | Sep 2018 → Aug 2024 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03461003 | Apr 2018 → Nov 2020 | early onset hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03417388 | Feb 2018 → Sep 2026 overdue | nonobstructive coronary artery disease | Cedars-Sinai Medical Center | Active not recruiting | Missed primary |
| Phase 4 | NCT03335904 | Jan 2018 → Aug 2019 | central sleep apnea syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT03371823 | Sep 2017 → Dec 2019 | hypertensive disorder | University of Delaware | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05713396 | Jan 2017 → Jun 2022 | diabetes mellitus | AHEPA University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02760615 | Nov 2016 → Aug 2020 | Crohn disease, ulcerative colitis | Takeda | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05827484 | Oct 2016 → Sep 2017 | — | Mostafa Hassanein, Msc | Completed | No outcome recorded |
| Phase 4 | NCT02416102 | Mar 2016 → Apr 2017 | chronic bronchitis | University of Miami | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT02188121 | Feb 2015 → Oct 2020 | bipolar disorder, cardiovascular disorder, major depressive disorder, schizoaffective disorder +1 | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02231125 | Sep 2014 → Jul 2016 | IgA glomerulonephritis | Chen Xiangmei | Unknown | No outcome recorded |
| Phase 4 | NCT02063100 | Feb 2014 → Jul 2015 | glomerulonephritis, proteinuria | Chinese PLA General Hospital | Unknown | Mixed |
| Phase 4 | NCT01766050 | Jan → Apr 2013 | transplant rejection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01529749 | Feb → Mar 2012 | HIV infectious disease | Felipe Garcia | Completed | No outcome recorded |
| Phase 4 | NCT01277822 | May 2011 → Apr 2013 | hypertensive disorder | Organon and Co | Completed | Missed primary |
| Phase 4 | NCT01180413 | Dec 2010 → Apr 2012 | essential hypertension | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01198496 | Oct 2010 → Dec 2017 | essential hypertension, stroke disorder | Biomedis International Ltd. | Unknown | Missed primary |
| Phase 4 | NCT00994617 | Jan 2010 → Dec 2014 | essential hypertension, resistant hypertension | University of Cambridge | Unknown | Mixed |
| Phase 4 | NCT00795847 | Nov 2008 → Nov 2010 | hypertensive disorder | Kurume University | Completed | No outcome recorded |
| Phase 4 | NCT01857999 | Sep 2008 → Feb 2011 | congestive heart failure | InCor Heart Institute | Completed | No outcome recorded |
| Phase 4 | NCT00720226 | Jul 2008 → Aug 2014 | chronic bronchitis, pulmonary emphysema | Johns Hopkins University | Completed | Missed primary |
| Phase 4 | NCT00701428 | Jun 2008 → Dec 2013 | hypertensive disorder, obstructive sleep apnea syndrome | Skaraborg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00669435 | Apr 2008 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT00496834 | Feb 2008 → Sep 2009 | hypertensive disorder | Organon and Co | Completed | Missed primary |
| Phase 4 | NCT00533858 | Sep 2007 → Sep 2008 | hypertensive disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01431508 | Aug 2007 → Jun 2009 | essential hypertension | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01830517 | Aug 2007 → Jun 2011 | hypertensive disorder, ischemic stroke | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT00663377 | Apr 2006 → Mar 2007 | heart failure | Tottori University Hospital | Completed | Met primary |
| Phase 4 | NCT01233635 | Nov 2005 → Nov 2007 | atrial fibrillation | University of Pittsburgh | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00239096 | Sep 2005 → Sep 2011 | alcoholic liver cirrhosis | Odense University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00419835 | May 2005 → Sep 2007 | diabetic kidney disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00157963 | Feb 2005 → Feb 2006 | essential hypertension | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00407862 | Jan 2005 → Jun 2006 | glucose intolerance, hypertensive disorder | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT00275639 | Dec 2004 → Aug 2007 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00237588 | Dec 2004 → Jul 2005 | hypertensive disorder | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00754429 | Jun 2004 → Jun 2009 | ischemic stroke | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00185094 | Feb 2004 → Jul 2005 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00168857 | Jul 2003 → Jun 2006 | diabetic kidney disease, hypertensive disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 4 | NCT00298714 | Mar 2003 → Jan 2006 | chronic hepatitis C virus infection, fibrotic liver disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT00140959 | Feb 2003 → Jun 2004 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00067990 | Dec 2002 → Jun 2011 | proteinuria | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT00155064 | Jul 2002 → Dec 2005 | primary aldosteronism | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00274638 | Jul 2002 → Jul 2003 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00140985 | Feb 2000 → Jan 2002 | kidney disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01115426 | Jan 1997 → Jan 2007 | IgA glomerulonephritis | University Magna Graecia | Completed | No outcome recorded |
| Phase not applicable37 trials · 1 met primary · 2 missed | ||||||
| — | NCT07513350 | Jan → Nov 2026 expected | frozen shoulder | Istanbul University | Recruiting | No outcome recorded |
| — | NCT06491940 | Aug 2024 → Jul 2025 overdue | proteinuria | RESnTEC, Institute of Research | Not yet recruiting | No outcome recorded |
| — | NCT06329076 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06329050 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT04606212 | Oct 2020 → Dec 2021 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT04606225 | Oct 2020 → Dec 2021 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT04604938 | Oct 2020 → Dec 2021 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT04604756 | Oct 2020 → Dec 2021 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT05828940 | Oct 2019 → Mar 2022 | post-traumatic stress disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT03604003 | Nov 2018 → Jun 2021 | chronic kidney disease | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03763409 | Mar → Sep 2018 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT03396523 | Jan → Oct 2018 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT03526042 | Sep 2017 → Jul 2019 | atherosclerosis, lupus nephritis | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| — | NCT02768948 | May 2017 → Sep 2019 | diabetic kidney disease | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| — | NCT02709018 | Jul 2016 → Feb 2020 | post-traumatic stress disorder | University of California, San Diego | Completed | Missed primary |
| — | NCT03434054 | Jun 2016 → Jun 2017 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT02190318 | Nov 2013 → Dec 2015 | chronic kidney disease | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT02446548 | Mar 2013 → Apr 2014 | proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| — | NCT01858623 | Feb → Mar 2013 | — | Damanhour University | Completed | No outcome recorded |
| — | NCT03563287 | Jan 2012 → Dec 2014 | morbid obesity | University of Eastern Finland | Completed | No outcome recorded |
| — | NCT01390181 | Sep 2011 → Jan 2014 | aortic valve disorder, thoracic aortic aneurysm | University of Michigan | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01321021 | Mar → Jul 2011 | — | University of Basel | Completed | No outcome recorded |
| — | NCT00879879 | Mar 2009 → Mar 2012 | precancerous condition | University of South Florida | Completed | No outcome recorded |
| — | NCT00880386 | Mar 2009 → Apr 2010 | lung cancer, postinflammatory pulmonary fibrosis | University of South Florida | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00732407 | Sep 2008 → Sep 2009 | atherosclerosis, type 2 diabetes mellitus | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00732966 | Sep 2008 → Sep 2009 | hypertensive disorder | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00561704 | Apr → Oct 2007 | diabetic kidney disease, obesity disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT00774904 | Apr → Oct 2007 | diabetic kidney disease | Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT00602004 | Oct 2006 → Aug 2014 | end stage renal failure | Melbourne Health | Completed | Missed primary |
| — | NCT00361023 | Jan → Jul 2006 | diabetic kidney disease, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT00907374 | Jul 2005 → Apr 2009 | proteinuria | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
| — | NCT00402194 | Jun 2005 → Nov 2011 | glucose intolerance, obesity disorder, prediabetes syndrome | Indiana University | Completed | No outcome recorded |
| — | NCT00617877 | Mar 2005 → Jun 2009 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| — | NCT01011062 | Jan 2004 → Oct 2007 | type 2 diabetes mellitus | Institute for Clinical and Experimental Medicine | Completed | No outcome recorded |
| — | NCT00162474 | Sep 2003 → Dec 2030 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| — | NCT00338091 | Jan 2002 → May 2006 | chronic kidney disease, proteinuria | Southern Medical University, China | Terminated | No outcome recorded |
| — | NCT00530595 | — | cardiovascular disorder | Saitama Medical University | Completed | Met primary |
| Comparator or background therapy139 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT02704494 Background | Mar 2016 → Feb 2017 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | Mixed |
| Phase 0 | NCT01210430 Comparator | Jul 2010 → Jun 2015 | postural orthostatic tachycardia syndrome | New York Medical College | Completed | No outcome recorded |
| Phase 0 | NCT00720577 Comparator | Dec 2005 → Jul 2007 | peripheral arterial disease | Medtronic Endovascular | Completed | No outcome recorded |
| Phase 1 | NCT05090449 Comparator | May 2019 → Apr 2020 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Show all 139 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2026-09-22 | Hanmi Pharmaceutical Company Limited | Results 한미약품 “‘ 아모잘탄’ 성분 기반 병용요법 임상적 가치 주목” hanmi.co.kr ↗
그 결과, 로사르탄 병용요법군은 비교 대상 ARB 가운데 유일하게 복용 중단군 대비신규 통풍 발생 위험 감소와 연관된 결과(HR 0.904, 95% CI 0.877-0.932)를 보였다. |
| 2025-06-13 | Hanmi Pharmaceutical Company Limited | Regulatory “고혈압 1차 치료의 새로운 길”…한미약품 ‘아모프렐’ 출격 준비 hanmi.co.kr ↗
한미약품은 최근 식품의약품안전처로부터 저용량 3제 항고혈압제 ‘아모프렐정’의 품목허가를 획득하고 출시를 위한 채비에 들어갔다고 13일 밝혔다. |
| 2023-05-04 | Hanmi Pharmaceutical Company Limited | Regulatory 한미, 저용량 이뇨제 붙인 고혈압 복합제 허가...라인업 지속 확장 hanmi.co.kr ↗
한미약품은 최근 식품의약품안전처로부터 고혈압 치료 복합신약 ‘클로잘탄정 50/6.25mg’을 신규로 허가 받았으며, 오는 7월초 제품을 출시할 예정이라고 밝혔다. |
| 2022-06-02 | Hanmi Pharmaceutical Company Limited | Regulatory 한미, 고혈압 복합신약 라인업 확대...’클로잘탄’ 허가 획득 hanmi.co.kr ↗
한미약품(대표이사 우종수·권세창)은 최근 식품의약품안전처로부터 ARB 계열 성분 ‘로사르탄(Losartan)’과 Thiazide-like 계열 이뇨제 성분 ‘클로르탈리돈(Chlorthalidone)을 결합한 2제 고혈압 치료 복합제 ‘클로잘탄정’ 2개 용량(50/12.5mg, 100/12.5mg)을 허가 받았다고 2일 밝혔다. |
| 2021-02-01 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 세계 최초 4제 복합신약 ‘아모잘탄엑스큐’ 출시 hanmi.co.kr ↗
임상 결과, 아모잘탄엑스큐는 Losartan 단독 요법으로 조절되지 않는 환자에게 추가로 약 15.8mmHg의 수축기 혈압 강하 효과를 보였으며, 기저치 대비 약 59%의 LDL-C 감소 효과도 보였다. |
| 2019-11-14 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “아모잘탄패밀리, 고혈압치료 병용시 우선적 권고 근거 충분” hanmi.co.kr ↗
대한고혈압학회에서 주관했던 The K-Central study는 병용 요법에 있어 CCB와 ARB의 조합인 아모잘탄이 ARB와 이뇨제의 병용 요법보다 우수한 중심혈압 및 활동혈압 조절 효과를 증명했다 |
| 2019-09-18 | Hanmi Pharmaceutical Company Limited | Results <보도자료> '아모잘탄 우수성 글로벌 입증'...SCI급 국제학술지에 11번째 등재 hanmi.co.kr ↗
연구 결과에 따르면, 투여 20주 후 경동맥-대퇴동맥의 맥파전달속도(ambulatory carotid femoral Pulse Wave Velocity, 이하 맥파전달속도) 변화량이 아모잘탄 투여군에서 유의하게 감소하는 결과를 보였다. |
| 2019-05-31 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 발매 10주년 맞은 아모잘탄, 국제학술지 10번째 등재 hanmi.co.kr ↗
특히, 투여 20주 후의 24시간 실시간 중심ㆍ활동혈압 변화는 아모잘탄 투여군(각각 -9.4, -10.1mmHg)이 ARB/HCTZ 투여군(각각 -6.3, -6.7mmHg)보다 통계적으로 우월한 것으로 나타났다. |
| 2019-05-22 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “고혈압치료의 모범답안”...아모잘탄패밀리 1알에 담겼다 hanmi.co.kr ↗
김 교수는 “고혈압 환자들의 목표혈압 도달을 위해서는 2제 이상의 항고혈압제가 필요한데, 아모잘탄은 ARB/HCTZ 2제 병용요법 대비 비열등한 강압 효과를 보여준 동시에 요산 감소 효과를 기대할 수 있다”고 말했다. |
| 2018-06-12 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 아모잘탄·로벨리토 임상 결과 유럽고혈압학회 발표 hanmi.co.kr ↗
연구결과, 아모잘탄 투여군에서 ARB/hydrochlorothiazide 복합제 투여군 대비, 24시간 활동혈압 중 수축기 혈압의 조절 효과가 우수하게 나타났으며, 야간의 수축기 중심혈압과 맥파전달속도(PWV, Pulse Wave Velocity), 평탄지수(SI, Smoothness Index)와 같은 혈역학적 지수에 있어 우수한 조절 효과를 보였다. |
| 2018-05-23 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “임상적 효과 입증한 아모잘탄 패밀리, 용량 선택도 다양” hanmi.co.kr ↗ |
| 2017-11-21 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품 ‘아모잘탄큐’ 3상 결과 SCI급 국제학술지 등재 hanmi.co.kr ↗
임상 결과, 아모잘탄큐 투여군은 Losartan/Rosuvastatin 투여군과 비교하여 투여 8주 후 SBP 기준 12mmHg 더 강력한 강압 효과를 나타냈으며, 투여 4주차 시점에서 약 96%의 우수한 혈압반응률을 보였다. |
| 2017-11-07 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 대한고혈압학회서 ‘아모잘탄 패밀리’ 심포지엄 hanmi.co.kr ↗ |
| 2017-10-19 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품 ‘아모잘탄플러스’ 3상 결과, SCI급 국제학술지 등재 hanmi.co.kr ↗
임상 결과, 아모잘탄플러스 투여군이 Amlodipine/Losartan 2제 요법 투여군과 비교하여 기저치 대비 8주 후 sitSBP를 평균 9.5mmHg 더 감소시키는 결과를 보였다. |
| 2017-10-13 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 대한심장학회서 ‘아모잘탄 패밀리’ 심포지엄 열어 hanmi.co.kr ↗ |
| 2017-07-24 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> “한미 1등 브랜드 아모잘탄, ‘패밀리’로 진용 갖췄다” hanmi.co.kr ↗
한미약품은 최근 혈압을 떨어뜨리는데 효과가 있는 이뇨제 성분 ‘클로르탈리돈’을 아모잘탄에 결합한 ‘아모잘탄플러스’와, 아모잘탄에 고지혈증치료 성분 ‘로수바스타틴’을 더한 ‘아모잘탄큐’의 시판허가를 각각 받았다. |
| 2017-07-17 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미, 고혈압+고지혈증 치료 3제 복합신약 허가 hanmi.co.kr ↗
한미약품(대표이사 우종수·권세창, www.hanmi.co.kr)이 2가지 고혈압치료 성분과 1가지 고지혈증 치료 성분을 합친 3제 복합신약 ‘아모잘탄큐’의 식약처 시판허가를 받았다고 17일 밝혔다. |
| 2017-06-30 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미, 고혈압치료 3제 복합신약 ‘아모잘탄플러스’ 허가 hanmi.co.kr ↗
한미약품(대표이사 우종수·권세창, www.hanmi.co.kr)은 지난 29일 고혈압치료 3제 복합신약인 ‘아모잘탄플러스’의 시판허가를 식품의약품안전처로부터 받았다고 30일 밝혔다. |
| 2016-09-29 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 세계고혈압학회서 ‘아모잘탄’ 우수성 입증 hanmi.co.kr ↗
임상 결과에 따르면, 두 투여군은 진료실 혈압(Office BP)에서는 차이를 보이지 않았으나, 24시간 중심혈압 및 활동혈압에서 아모잘탄이 Losartan+HCTZ 복합제 대비 더 우수한 강압효과를 나타냈다. |
| 2010-04-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Final Approval of Generic Hyzaar® and Cozaar® tevapharm.com ↗
Jerusalem, April 7, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium). |
| 2006-06-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application ("ANDA") for Losartan Potassium and Hydrochlorothiazide Tablets, 50 mg/12.5 mg and 100 mg/25 mg. |
| 2006-05-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval for Generic Cozaar® Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's antihypertensive agent Cozaar® (Losartan Potassium) Tablets, 25 mg, 50 mg and 100 mg. |
All press releases naming this drug 23 releases
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 396 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Losartán | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗374“HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone...” NCT06831864 ↗ “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with...” NCT04049734 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO)...” NCT07704658 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the...” NCT07569640 ↗ “Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for...” NCT01145612 ↗ “The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and...” PMID 29150250 ↗ Nov 2017 “Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose...” PMID 24990091 ↗ Jul 2014 |
| Known as | Allisartan | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Angizaar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Aradois | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Cozaar | “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗20“This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗ “in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till...” NCT05827484 ↗ “They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week” NCT01675362 ↗ “The commonly prescribed antihypertensive drug losartan (brand name: Cozaar; UK licensed for 20 years)” NCT03763409 ↗ “COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist.” NCT03217825 ↗ “single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)” NCT06636812 ↗ “MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan)” NCT02200653 ↗ “losartan 100 mg tablets (test) versus Cozaar® (reference)” NCT01124162 ↗ “7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA” NCT07017023 ↗ “oral single-dose losartan potassium (Cozaar; 50mg)” NCT06628154 ↗ |
| Known as | Cozaar Tab. | “Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg” NCT05843162 ↗ |
| Known as | Cozaar: losartan | “Cozaar: losartan” NCT00981747 ↗ |
| Known as | COZZAR | “Losartan (COZZAR®)” NCT07784621 ↗1“Losartan (COZZAR®)” NCT05090449 ↗ |
| Known as | Cozzar tablet | “Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks” NCT01766505 ↗ |
| Known as | DU PONT-753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | DUP 753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Dup-89 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | E-3340 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | HGP1405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04252872 ↗ |
| Known as | L-158086 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | L50 | “50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5)” NCT01302691 ↗ |
| Known as | LORZAAR | “MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan)” NCT02200653 ↗ |
| Known as | LOS | “olmesartan medoxomil (OM) versus losartan potassium (LOS)” PMID 22763801 ↗ Jul 2012 |
| Known as | Losacar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losaprex | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | losartan (Cozaar) | “losartan (Cozaar)” NCT02238457 ↗ |
| Known as | losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA) | “losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA)” NCT00519870 ↗ |
| Known as | Losartan (generic name) | “Losartan (generic name)” NCT01124175 ↗ |
| Known as | Losartan also known as Cozaar | “Losartan also known as Cozaar” NCT01051219 ↗ |
| Known as | Losartan monopotassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | losartan potassium | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗31“This study will compare the advantages and disadvantages of azilsartan and classical ARB drug losartan potassium in terms of proteinuria, blood pressure control and renal...” NCT05753696 ↗ “Losartan potassium (losartan) is an angiotensin II receptor blocker (ARB) that reduces PAI-1 production and improves insulin sensitivity that has been proposed as a treatment...” PMID 29992039 ↗ Jun 2018 “IgAN patients will be randomized assigned to the Abelmoschus manihot group (in the form of a huangkui capsule, 2.5 g, three times per day) and the losartan potassium group...” PMID 28395659 ↗ Apr 2017 “Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks” NCT01766505 ↗ “Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype” NCT03467217 ↗ “COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist.” NCT03217825 ↗ “Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.” NCT05090449 ↗ “single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)” NCT06636812 ↗ “MK0954, losartan potassium / Duration of Treatment - 12 weeks” NCT00449111 ↗ “MK0954, losartan potassium/Duration of Treatment: 20 weeks” NCT00140985 ↗ |
| Known as | Losartan potassium component of hyzaar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losartic | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losata | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Lozap | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | LST | “The antihypertensive efficacy and tolerability of losartan (LST) in fixed combination with hydrochlorothiazide (HCTZ) has not been compared to those of amlodipine monotherapy in Asians.” PMID 19949604 ↗ Apr 2009 |
| Known as | MK0954 | “MK0954, losartan potassium / Duration of Treatment - 12 weeks” NCT00449111 ↗4“MK0954, losartan potassium/Duration of Treatment: 20 weeks” NCT00140985 ↗ “MK0954, losartan potassium/Duration of Treatment: 18 weeks” NCT00140959 ↗ “MK0954, losartan / Duration of Treatment: mean 3.4 years” NCT00308347 ↗ “Losartan (MK0954) / Losartan + HCTZ (MK0954A)” NCT00546052 ↗ |
| Known as | MK0954, /Duration of Treatment : 5 Years | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00338260 ↗ |
| Known as | NSC-758699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Nu-lotan | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Presartan-50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Reslio | “Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide)” NCT03978884 ↗ |
| Known as | Tancin | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Zaart | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Action | Inhibit | “Specific Aim 1 To recruit 285 type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria into a 5-year study to...” NCT00143949 ↗1“Type-1 angiotensin II receptor antagonist” CHEMBL191 ↗ |
| Modality | Other / unclassified | “angiotensin receptor blocker” NCT02190318 ↗ |
| Route | Oral | “50-mg losartan oral tablet” NCT00090259 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL191 ↗ |
| Target | TGFB1 | “Losartan is a known anti-fibrotic agent via blocking of TGF-B1.” NCT04212650 ↗ |